Mirdametinib in Histiocytic Disorders

Clinical trial NCT06153173 · RECRUITING

Trial details

NCT number: NCT06153173
Sponsor: Children's Hospital Medical Center, Cincinnati
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Langerhans Cell Histiocytosis (LCH)Juvenile Xanthogranuloma (JXG)Rosai-Dorfman Disease (RDD)Histiocytic Disorders

Start date: 2024-02-05
Primary completion: 2030-03-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.